| Authors | Eapen, Mathew Suji Hansbro, Philip M Larsson‑Callerfelt, Anna-Karin Jolly, Mohit K Myers, Stephen Sharma, Pawan Jones, Bernadette Rahman, Md Atiqur Markos, James Chia, Collin |
|---|---|
| Type | Journal Article (Original Research) |
| Journal | Drugs |
| PubMed ID | 30392114 |
| Year of Publication | 2018 |
| URL | https://www.ncbi.nlm.nih.gov/pubmed/30392114 |
| DOI | https://doi.org/10.1007/s40265-018-1001-8 |
| Abstract | Chronic obstructive pulmonary disease (COPD) and lung cancer are major lung diseases affecting millions worldwide. Both diseases have links to cigarette smoking and exert a considerable societal burden. People suffering from COPD are at higher risk of developing lung cancer than those without, and are more susceptible to poor outcomes after diagnosis and treatment. Lung cancer and COPD are closely associated, possibly sharing common traits such as an underlying genetic predisposition, epithelial and endothelial cell plasticity, dysfunctional inflammatory mechanisms including the deposition of excessive extracellular matrix, angiogenesis, susceptibility to DNA damage and cellular mutagenesis. In fact, COPD could be the driving factor for lung cancer, providing a conducive environment that propagates its evolution. In the early stages of smoking, body defences provide a combative immune/oxidative response and DNA repair mechanisms are likely to subdue these changes to a certain extent; however, in patients with COPD with lung cancer the consequences could be devastating, potentially contributing to slower postoperative recovery after lung resection and increased resistance to radiotherapy and chemotherapy. Vital to the development of new-targeted therapies is an in-depth understanding of various molecular mechanisms that are associated with both pathologies. In this comprehensive review, we provide a detailed overview of possible underlying factors that link COPD and lung cancer, and current therapeutic advances from both human and preclinical animal models that can effectively mitigate this unholy relationship |
http://www.ibas.org.au/what-we-do/publications/3873005
HEALTHY MALES AND FEMALES WANTED FOR SLEEP STUDY
Interested to participate in a study investigating the effect of fatigue on driving performance?
Interstitial lung disease (ILD) is a chronic lung condition that causes stiff lungs and restricts sufferers from taking a deep breath. Exercise in a gym, such as walking or riding a bike, can help make...
Sleep apnea is a condition where breathing is abnormal during sleep. There are two main forms of sleep apnea: obstructive and central. For obstructive sleep apnea, breathing is reduced because the airway...
IBAS RESEARCHER FEATURED ON NHMRC TRACKER MAGAZINE
Prof Anne Holland's research on chronic obstructive pulmonary disease is featured as one of the 10 best research topics in the NHMRC publication, Tracker.
GOOD SLEEP MORE ESSENTIAL THAN EVER DURING COVID-19
This Sleep Awareness Week, Austin Health's sleep experts remind us all that sleep is integral to good health, particularly at times when we're under stress.
PROFESSOR DAVID BERLOWITZ RECEIVES OVER 7 MILLION IN GRANTS
University of Melbourne Chair of Physiotherapy at Austin Health, Professor David Berlowitz has had quite a memorable week.
DO YOU HAVE SPINAL CORD INJURY? TIRED? GET TREATED!
Melbourne researchers have found that 80 percent of people with quadriplegic spinal injuries have sleep apnoea. It's having a big effect on their lives but they don't know they have it, and they don't know it can be treated.
© 2021 Institute for Breathing and Sleep. All Rights Reserved. ABN 39 093 685 879
Powered by Helmut Design | Manage
